Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03441113 · ClinicalTrials.gov registry record · Phase 2

Extended Access of Momelotinib in Adults With Myelofibrosis

A Phase 2 study of Neoplasms and Primary Myelofibrosis (PMF), sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
237
Enrollment target
20
Study locations

NCT03441113 is a Phase 2 study of Neoplasms and Primary Myelofibrosis (PMF) that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 237 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03441113, a Phase 2 study of Neoplasms and Primary Myelofibrosis (PMF), is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
237 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg and 200 mg tablets) and have not experienced progression of disease. The secondary objective is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.

Conditions Studied

Neoplasms Primary Myelofibrosis (PMF) Post-polycythemia Vera Myelofibrosis (Post-PV MF) Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions

  • DRUG MMB

Study Locations (20)

Florida

  • GSK Investigational Site - Jacksonville
  • Mayo Clinic Florida - Jacksonville
  • GSK Investigational Site - Tampa
  • Moffitt Cancer Center - Tampa

California

  • IC Irvine Health - Orange
  • GSK Investigational Site - Stanford
  • Stanford Hospital and Clinics - Stanford

Colorado

  • GSK Investigational Site - Aurora
  • University of Colorado Cancer Center - Aurora

Georgia

  • GSK Investigational Site - Atlanta
  • Winship Cancer Institute, Emory University - Atlanta

Maryland

  • GSK Investigational Site - Baltimore
  • Saint Agnes Hospital - Baltimore

Massachusetts

  • Dana-Farber Cancer Institute (DFCI) - Boston
  • GSK Investigational Site - Boston

Minnesota

  • GSK Investigational Site - Rochester
  • Mayo Clinic - Department of Hematology - Rochester

Missouri

  • Washington University School of Medicine Siteman Cancer Center - St Louis
  • GSK Investigational Site - St Louis

Trial Details

FieldValue
Enrollment Target 237 participants
Start Date 2018-05-03
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03441113

The ClinicalTrials.gov registry entry for NCT03441113 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which MMB is the first listed.

NCT03441113 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT03441113 about?

NCT03441113 is a clinical study titled "Extended Access of Momelotinib in Adults With Myelofibrosis". The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT0196983...

What is the current status of trial NCT03441113?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2018-05-03. Estimated completion is 2026-12-31.

What conditions does trial NCT03441113 study?

This clinical trial studies the following conditions: Neoplasms, Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF).

What interventions are being tested in trial NCT03441113?

The interventions under investigation include: MMB (DRUG).

Who is sponsoring clinical trial NCT03441113?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03441113 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Primary Myelofibrosis (PMF)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.